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Abstract
At the “5th International Meeting on Inflammatory Bowel Diseases selected topics of inflammatory
bowel disease (IBD), including the environment, genetics, the gut flora, the cell response and
immunomodulation were discussed in order to better understand specific clinical and therapeutic
aspects. The incidence of IBD continues to rise, both in lowand in high-incidence areas. It is believed
that factors associatedwith ‘Westernization’maybeconditioning theexpression of these disorders.
The increased incidence of IBD among migrants from low-incidence to high-incidence areas within
the same generation suggests a strong environmental influence.
The development of genome-wide association scanning (GWAS) technologies has lead to the
discovery of more than 100 IBD loci. Some, as the Th 17 pathway genes, are shared between
Crohn's disease (CD) and ulcerative colitis (UC), while other are IBD subtype-specific (autophagy
genes, epithelial barrier genes). Disease-specific therapies targeting these pathways should be
developed. Epigenetic regulation of the inflammatory response also appears to play an important
role in the pathogenesis of IBD.
The importance of gut flora in intestinal homeostasis and inflammation was reinforced, the
concepts of eubiosis and dysbiosis were introduced, and some strategies for reverting dysbiosis to
a homeostatic state of eubiosis were proposed. The current status of studies on the human gut
microbiota metagenome, metaprotome, and metabolome was also presented.
The cell response in inflammation, including endoplasmic reticulum (ER) stress responses,
autophagy and inflammasome-dependent events were related to IBD pathogenesis. It was
suggested that inflammation-associated ER stress responses may be a common trait in the
pathogenesis of various chronic immune and metabolic diseases.
How innate and adaptive immunity signaling events can perpetuate chronic inflammation was
discussed extensively. Signal transduction pathways provide intracellular mechanisms by which
cells respond and adapt to multiple environmental stresses. The identification of these signalsof Internal Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of L'Aquila,
67100 L'Aquila, Italy. Tel.: +39 0862 434736; fax +39 0862 434761.
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691News from the “5th international meeting on inflammatory bowel diseases” CAPRI 2010has led to a greater mechanistic understanding of IBD pathogenesis and pointed to potentially
new therapeutic targets.
A critical analysis of clinical trials and of risk-benefit of biological therapy was presented. The
problem of Epstein–Barr virus (EBV) and lymphoma in IBD was extensively discussed. Lymphomas
can develop in intestinal segments affected by IBD and are in most cases associated with EBV. The
reasons of treatment failure were also analyzed both from basic and clinical points of view.
Two very interesting presentations on the integration of research and clinical care in the near
future closed the meeting. These presentations were focused on macrotrends affecting
healthcare delivery and research, and the need to innovate traditional infrastructures to deal
with these changing trends as well as new opportunities to accelerate scientific knowledge.
© 2010 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.Contents
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Diseases was held in Capri (Italy) from April 8 to 10, 2010,
under the presidency of R. Caprilli (Italy). The meeting was
restricted to 120 participants including invited speakers,
authors (young investigators) of selected papers, and
“thought leaders”. The structure of the meeting consisted
of 8 sessions, in which selected basic aspects of IBD,
including the environment, genetics, the gut flora, the cell
response and immunomodulation were used in order to
improve understanding of and discuss specific clinical and
therapeutic aspects. The meeting was designed to be very
interactive and focused more on basic science rather than
purely clinical topics. The key objectives of Capri 2010 were:
1) Update knowledge in key areas of IBD pathogenesis; 2)
Incorporate into IBD emerging scientific concepts by inviting
top experts in areas outside of IBD; 3) Ponder about the
future rather than discuss already existing information; and
4) Attract and retain the brightest young investigators in the
field of IBD. The aim of this article is to summarize and
outline the scientific news presented and discussed at the
Capri 2010 meeting.1. Environment and disease pathogenesis
The incidence of IBD continues to rise, even in high-incidence
areas. It has been estimated that the prevalence of IBD in the
general population may be as high as 0.4–0.5% in North
America (United States and Canada), translating into
approximately 1.4 million persons with these chronicintestinal disorders.1 In the United States, it is estimated
that IBD accounts for 1.4 to 1.9 million outpatient visits, 90
to 200 thousand hospitalizations, and approximately $2.1
billion in direct and indirect costs in 2004 (E.V. Loftus, USA).
The incidence and prevalence of ulcerative colitis (UC)
and Crohn's disease (CD) are also increasing in areas that
historically were thought to be low-incidence areas, such as
East Asia, the Indian subcontinent, the Middle East, Latin
America, and Eastern Europe.2 It is believed that factors
associated with ‘Westernization’ may be conditioning the
expression of these disorders.3,4 The increased incidence of
IBD among migrants from low-incidence to high-incidence
areas, within one generation (e.g., South Asians), is also
suggestive of a strong environmental influence. A North–
South gradient has been reported, not just in IBD but also in
other immune-mediated disorders.5,6 Racial and ethnic
differences are also present: Mexican-Americans are more
likely to develop UC than CD (more proximal disease extent,
fewer extraintestinal manifestations, high prevalence of
pANCA ), whereas African-Americans are more likely to
develop CD (more colonic or perianal, less ileal, more
arthritis and uveitis).7
The two best understood environmental influences on the
expression of IBD continue to be cigarette smoking and
appendectomy. Both of these factors are associated with a
reduced incidence of UC, while quitting smoking is associ-
ated with an increased risk of UC. Smoking is a risk factor for
CD and increases its severity, and appendectomy may be a
weak risk factor for CD. Intriguing reports on the role of
drinking water quality and air quality on the incidence of IBD
692 G. Latella et al.have recently appeared in the literature, but confirmatory
studies are needed before we conclude that they represent
true risk factors.
Modern lifestyle might alter another environmental
factor, the enteric microflora. Thus may occur in different
ways: improved sanitation, decline in endemic parasitism,
decreased exposure to soil microbes, decline in Helicobacter
pylori infection, increased antibiotic usage, less crowded
living conditions, refrigeration, sedentary lifestyle, obesity,
and increased consumption of refined sugars and saturated
fats.4 Diet as a risk factor is difficult to study and may act
indirectly via the microflora. Future studies need to focus on
dietary patterns rather than individual foods.8
The results of studies of early life influences and risk of
IBD have been, at best, conflicting. While the hygiene
hypothesis, postulating that lack of early exposure to
common pathogens or commensal bacteria might result in
abnormal immune response to these antigens later in life,
remains attractive, this has not been borne out in a
consistent fashion across studies at the clinical or population
level. In regard to the relation between psychological stress
and IBD, recent systematic review of 18 prospective studies
examining stress as a risk factor for disease exacerbations
showed a significant association, and coping behaviors
appear to modulate the effect of stress.9
Future directions should focusmore on the gutmicrobiota,
the effect of diet on microbiota, early life events, migration
from low-prevalence to high-prevalence areas, and residents
of transitioning societies (developing to developed).
Epidemiological studies of human diseases should not only
be aimed at providing data on their prevalence and
incidence, but should generate hypothesis stimulating
further experimental research for a better understanding
of their pathogenesis and management. Like IBD, asthma and
allergic diseases have a very high and increasing prevalence
worldwide (S. Bonini, Italy). Comparing epidemiological data
of asthma and allergic diseases to those of IBD may help
understand similarities and differences in these chronic
debilitating inflammatory conditions. Among the various
factors suggested to be responsible for the increasing
prevalence of asthma and allergic diseases are environmen-
tal changes, declining prevalence of microbial burden, lack
of physical exercise and diet,10 all of which also apply to IBD.
In particular, in regard to the tight relationship between
microbial stimulation of the immune system and the
prevalence of allergic diseases, the prominent role of the
gut in modulating innate and adaptive immune responses
appears not to be restricted to the gut but also highly
relevant to other systemic inflammatory conditions.
Immune-mediated inflammatory conditions, like IBD,
exert their effects through various cells and the proinflam-
matory mediators they secrete. Prominent among these are
CD4-positiveT cell subsets and their related cytokines. In
addition to the two classical T helper 1 (Th1) and Th2 cells,
the Th 17 subset must also be considered (B. Stockinger, UK).
IL-17 producing T cells are generated by a unique mixture of
conditioning cytokines, including IL-6, IL-23 and TGF-β. IL-17
mainly mediates adaptive immune responses against patho-
gens (fungi, bacteria) but seems to also be involved in
autoimmune syndromes and IBD.11
IL-17 and IL-22, both Th17-derived cytokines, are strongly
up regulated in IBD but the distinction between beneficialand pathological effects for these two cytokines is still
unclear. A low level of IL-17 expression is beneficial for gut
homeostasis and barrier function. IL-17 has been shown to
promote tight junction formation and mucin secretion. IL-22
plays a role in the induction of defensins (antimicrobial
peptides) and is therefore important in the response against
gut pathogens. On the other hand, excessive IL-17 and IL-22
expression correlates with intestinal inflammation.
It has been recently shown that the Th17 program is
modulated by interaction with endogenous and environmen-
tal stimuli that trigger the aryl hydrocarbon receptor
(AHR).11–13 Both endogenous and exogenous AHR ligands
influence Th17 cell response: this may be beneficial
(induction of IL-22 for mucosal defense, wound healing) or
detrimental (exacerbation of Th17-mediated autoimmuni-
ty). It is likely that endogenous AHR ligands play a role in
mucosal homeostasis. A wide variety of potential AHR ligands
from the commensal flora as well as dietary components may
be involved. It still remains to be determined to what extent
AHR activation due to interactions with gut flora or food
constituents or chemical pollutants influences IBD pathology
and the function of intestinal IL-17 producing T cells.
Aluminum worsens intestinal inflammation and delays
mucosal repair in experimental models of colitis, suggesting
that is an environmental microparticle that could participate
to the dysregulation of intestinal homeostasis and IBD
(G. Pineton de Chambrun, France). Aluminum is a contaminant
which could be involved in IBD pathophysiology in two ways.
First, for environmental reason: aluminum is a common metal
with ubiquitous distribution (water, soil, atmosphere), it
contaminates vegetables and drinking water, and human
activities increase aluminum bioavailability (industries, inten-
sive farming, alimentary additives, drugs, etc); after oral
intake, aluminum could interact with intestinal mucosa and
the local immune system. Second, for biological reason:
aluminum increases immune response in vitro (it acts as a
vaccine adjuvant), induces granulomas and epidemic granu-
lomatous enteritis in horses.2. Genetics and disease pathogenesis
M. Parkes (UK) emphasized that the development of genome-
wide association scanning (GWAS) technologies has lead to the
discovery N100 confirmed IBD loci.14–16 Some, as the Th17
pathway genes (IL23R, IL12B, JAK2, STAT3), are shared
between CD and UC, while others are IBD phenotype-specific
(autophagy gene as ATG16L1, IRGM and NOD2 for CD;
epithelial barrier genes HNF4a, E-Cadherin, LAMB1 and IL-10
for UC). Disease-specific therapies targeting these pathways
should be considered.
The capacity of genetic findings in predicting who might
develop IBD in the future remains limited. A more useful
application would be the detection of genetic markers
which, when combined with other biomarkers and clinical
data, might predict disease course. Such markers have yet to
be developed but the appropriate studies are underway.
Additional pharmacogenetic insights are also likely to be
gleaned through the analysis of GWAS data. The hope is that
genetic studies can bring to light pathways of primary
importance in IBD pathogenesis, and that some of these
might be amenable to therapeutic manipulation.
Figure 1 Coremicrobiomeof the “normal”microbiota of healthy
subjects.
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genetic studies (R. Duerr, USA). Where is the rest of the
missing heritability? The ‘common disease, common variant’
hypothesis states that common complex diseases are due, at
least in part, to disease loci with one or only a few common
genetic risk variants, each with relatively small effects. Are
there more of such loci to be found? Do IBD loci identified in
GWAS of common variants also harbor low frequency IBD-
associated variants that may have larger effect sizes? Do
unique families with multiple IBD members carry rare
disease-causing variants? What about copy number and
other types of structural variants? Answers to these
important questions are expected from ongoing and future
studies.
Instead of working from genotype to phenotype, perhaps
working backwards from phenotype to genotype in the
search for IBD genes might be an alternative option, as
suggested by Abreu MT, USA.
Genetically heterogeneous, dominant diseases provide a
significant challenge compared to recessive syndromic
phenotypes. To genetically confirm any suspected disease-
causing gene, one has to identify additional mutations in
families with the same phenotype. Even without power for
conclusive logarithm of odds (LOD) scores, the calculation of
exclusion LOD scores or shared genomic regions can be very
helpful. Exome enrichment and sequencing is never com-
prehensive, variants will be inherently missed. Thus, it is a
good strategy to study a number of families, and do not bet
everything on a single pedigree.
Next generation, high throughput sequencing has many
applications that are useful for the study of IBD. Exomic
sequencing is here; whole genome sequencing is next.
Clinicians and investigators must identify distinct (some-
times rare) phenotypes through a variety of approaches
including molecular and immunological ones. Microbiologic
characterization of these distinct phenotypes will be
necessary for the study to be complete. To genetically
confirm any suspected disease-causing gene, one has to
identify additional mutations in families with the same
phenotype and ideally have more than one pedigree.
Genetic variants might partially modulate linear growth
in pediatric-onset CD (J.J. Lee, USA). A significant associa-
tion between growth impairment in CD and a stature-related
polymorphism in the dymeclin gene (DYM) has been found. In
addition, there is over-transmission of two CD-susceptibility
alleles, 10q21.1 intergenic region (rs10761659) and ATG16L1
(rs10210302), in growth-impaired CD children. Further
studies need to validate these associations and investigate
other stature and CD-susceptibility loci associated with the
growth-impaired phenotype.
J. Lee (UK) reported that gene expression profiling of
separated CD8 T cells reveals a gene signature of prognostic
utility in IBD, as previously observed in systemic lupus
erythematosus and vasculitis. A common CD8 T cell gene
expression signature exists in both UC and CD. This is
detectable at diagnosis before any treatment is given. This
signature can divide patients into two distinct groups, which
are otherwise indistinguishable. Patients in each group have
significantly different disease courses: significantly shorter
time to need for treatment escalation, and significantly more
escalations required over time. These observations may have
important clinical implications: 1) Ability to identify patientsat diagnosis who are likely to run a more aggressive disease
course, and 2) Personalized use of aggressive medical
therapies (top-down).3. The gut flora: homeostasis or inflammation
The role of commensal intestinal microbiota in nutrition and
health, as well as in immune diseases was discussed in depth.
J. Doré (France) explained the complexity of composition
and function of the intestinal microbiota, including 100
trillion microorganisms (10 times the number of cells in the
human body, and containing N100 fold more genes than in
the human genome), mostly still to be cultured (~70% of
dominant species). Thus, the whole gut microbiome can be
considered a true organ that is geared up for protecting our
health and well-being throughout all stages of our life and
amenable to modulation.
The key interactions between food constituents,
microbes and the host derive from a long co-evolution,
resulting in a mutualistic association (microbiome and human
genome crosstalks). The human intestinal microbiota is
diverse in composition, and appears essentially subject-
specific, although its functionality is expected to be
relatively homogeneous among individuals. However, it is
not yet clear at which level – metagenome, metaproteome
or metabolome – this functional homogeneity can be
identified. At the phylogenetic level, in adults, N80% of
phylotypes belong to 3 major phyla (Bacteroidetes, Firmi-
cutes, and Actinobacteria) most of which are subject-
specific.17A few species (2%) are altogether more prevalent
(conserved among individuals) and more represented,
constituting a phylogenetic core. These mainly include
Faecalibacterium prausnitzii, Eubacterium rectale, Rumi-
nococcus bromii, Alistipes putredinis, Subdoligranulum sp,
Bacteroides vulgatus, Bacteroides uniformis rel, Parabac-
teroides distasonis, Bifidobacterium longum, and Dorea
formicigeneran. At the metaproteomic level, this translates
into a high proportion of conserved proteins in the micro-
biota (50–60%) (Fig. 1). Future studies will better define the
phylogenetic, metagenomic and functional core of the
intestinal microbiota.18
The dominant mucosa-associated microbiota appears dif-
ferent from the luminal faecal microbiota and at the same
time highly conserved in different segments of the intestine.
Molecular evaluation allows to define the normal microbiota,
694 G. Latella et al.or normobiosis, based on both static and dynamic parameters
related to composition and function. These parameters
include density, diversity, complexity, composition, core-
species, dynamics (stability and resilience) of structure and
functions (core microbiome). Hence, it becomes possible to
explore the dysbiosis of the dominant intestinal microbiota in
patients compared to healthy subjects. This opens novel fields
of exploration: 1) Mechanisms by which dysbiosis of the
intestinal microbiota acts in chronic, immune, metabolic or
degenerative pathologies, and 2) Rationale for designing
strategies to restore normobiosis/homeostasis.
Dysbiosis in CD is characterized by increased bacterial
density at the mucosal level, increased proportion of
immuno-agressive commensals (Gram-negative), reduced
proportion of anti-inflammatory commensals (Gram-positive
Firmicutes, Actinobacteria), and increased proportion of
proteins potentially promoting autoimmunity. Such dysbiosis
creates a vicious circle favoring aggravation and chronicity of
the disease.19,20 Very interesting is the anti-inflammatory
properties of F. prausnitzii proved either in in vitro
experiments (induction of high IL10/IL12 cytokine release
by peripheral blood mononuclear cells, reduction of IL-1β
induced IL-8 secretion by Caco-2 cells, and abolished TNF-α
induced NF-κB activity in HT-29 cells) and in vivo experi-
ments (both F. prausnitzii and its supernatant reduced blood
and tissue parameters of inflammation in trinitrobenzene
(TNBS)-induced colitis in Balb/c mice, and administered
intraperitoneally its supernatant protected mice from death
induced by TNBS).21
Microbiome specificities in immune-mediated diseases may
allow to identification of predictive biomarkers, new targets
and strategies for nutritional and/or therapeutic applications in
intestinal disorders. The International Human Microbiome
Consortium aims to gain an unprecedented view of the gut
microbiota and validate microbial signatures of prognostic and
diagnostic value. These approaches promise to identify themost
redundant genomic traits of the human intestinal microbiota,
thereby identifying the functional balance of this organ.
R.B. Sartor (USA) explained that since microbial compo-
sition is established in early life, a possible effect of host
genetics on commensal intestinal bacteria may occur.22,23
Genetic polymorphisms affect susceptibility to IBD by
altering bacterial composition as well as altering immune
responses to commensal bacteria and mucosal barrier
function. The possible mechanisms for genetic regulation
of enteric microbiota include altered Paneth cell function
and expression of antimicrobial peptides, altered mucus
production, altered secretion of IgA and IgM, and altered
innate and adaptive immune responses.24 CD could be
determined by genetic influences on antimicrobial peptide
expression. Genes associated with CD that affect bacterial
killing include Nod2 (defective α defensin production,
clearance of intracellular bacteria), ATG16L1 (autophagy,
killing and processing of phagocytosed bacteria), NCF4
(NADPH-mediated killing of phagocytosed bacteria), and
IRGM (IFN-γ induced killing of phagocytosed bacteria).
B. Chassaing (France) reported that increased numbers of
adherent-invasive Escherichia coli (AIEC) are associated with
Peyer's patches of CD patients compared to those of controls.
By expressing long polar fimbriae CD associated AIEC could
use Peyer's patches as an open gate to induce early events of
the disease pathogenesis.S. Müller (Switzerland) analyzed the local expression of
mannan-binding lectin (MBL) in the human intestine and
investigated the effect of MBL-deficiency in experimental
colitis with concurrent intestinal mucosal exposure to patho-
genic yeast and bacteria. Deficiency of MBL is associated with
increased prevalence of anti-Saccharomyces cerevisiae anti-
bodies (ASCA) and with complicated phenotypes of CD.
C. albicans and AIEC accelerate dextran sodium sulfate (DSS)
colitis in MBL-deficient mice. MBL prevents excessive dissem-
ination of C. albicans by supporting retention and clearance in
circulation. MBL supports innate control of gut pathogens
during inflammation.
D. Haller (Germany) put the gut microbiota and metab-
olism at the cross-road between homeostasis and chronic
inflammation. He explained that the gut interface acts as a
highly selective barrier and communication organ between
the luminal environment including food and bacterial
components and the host responsible for the regulation of
metabolic and immune functions.25 It is more and more
evident that chronic degenerative disorders, including type 2
diabetes and IBD, share similar diseases mechanisms at the
cellular level including endoplasmic reticulum (ER) stress
and mitochondrial dysfunctions with inflammatory processes
as an important disease-conditioning situation in various
target tissues26–29 (Fig. 2). Emerging evidence supports the
hypothesis that the ER and the mitochondrion share common
mechanisms in triggering the unfolded protein response
(UPR). It was reported that the cytoplasmic double stranded
RNA-activated protein kinase integrates the mitochondrial
stress response into ER-associated signaling pathways,
linking ER and mitochondrial UPR under conditions of chronic
inflammation.30,314. Cell response in inflammation
Intestinal epithelial cells (IEC) are key regulators for the
recruitment and instruction of other cells within epithelium
and lamina propria as well as the response to both
intraluminal commensal bacteria and pathogens. It remains
to be established whether IECs can be primary source of
signals for the development of intestinal inflammation.
R.S. Blumberg (USA) fully illustrated the relationship
between ER stress, Paneth cells and intestinal inflammation
mediated by the UPR.32,33 This represents a signaling
pathway from the ER to the nucleus that protects cells
from stress caused by unfolded or misfolded proteins. UPR
signaling is mainly driven by inositol-requiring, endoplasmic
reticulum-to-nucleus signaling protein 1α (IRE1α)-X-box-
binding protein-1 (XBP1) pathway (IRE1-XBP 1 pathway).
IRE1α is a transmembrane kinase/endoribonuclease
which initiates the non-conventional splicing of the messen-
ger RNA encoding a key transcription activator Hac1 in yeast
or XBP1 in metazoans. XBP1 is a key component of the ER
stress response, and is required for the differentiation and
function of certain secretory epithelia cells.
IRE1α is ubiquitous, whereas IRE1β is specifically ex-
pressed in the intestinal epithelium. IRE1α exhibits both
endoribonuclease activity – with XBP1 being the only known
substrate – and kinase activity that engages both JNK and
classical NF-κB pathways. XBP1 deletion causes ER stress
in the epithelium, spontaneous enteritis (mainly in ileum),
Figure 2 Signal transduction from the ER to the nucleus: highly preserved mechanisms of stress responses (Courtesy of D. Maller,
Germany).
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in the intestinal epithelia, decreases crypt bactericidal
function, and impaired Listeria monocytogenes clearance.
Stressed IECs with reduced or absent XBP1 activity
displayed evidence of heightened proinflammatory tone in
response to TNFα and flagellin, two known inducers of gut
inflammation through elevated IRE activity and JNK
phosphorylation.
ER stress is common in human IBD (both UC and CD).
Genetic and environmental factors can affect ER stress in the
intestinal epithelium and consequently inflammation.28,33,34
Genetic factors include either primary ER Stress (XBP1,
AGR2, ORMDL3) or secondary ER stress (HLAB27, Mucins,
ATG16L1). Environmental factors include bacteria, dietary
and drugs.
It is increasingly evident that autophagy has an important
role in chronic inflammation and in particular in the
pathogenesis of CD (R. Xavier, USA). Autophagy involves
the concerted action of cytoplasmic proteins that generate
curved isolation membranes to envelop cytoplasm, cytoplas-
mic organelles and intracellular pathogens. Autophagy
represents a host defense mechanism.35–37 Autophagy
degrades and recycles cellular contents and restricts
bacterial access to the cell cytoplasm. Autophagy requires
the action of two ubiquitin-like conjugation (Atg5/12/16L1
and Atg8/LC3) systems. This requirement is supported by the
finding that two genes involved in autophagic processes –
ATG16L1 and IRGM – are significantly associated with CD.
Recently two independent labs have linked NOD2 and
autophagy.38,39 NOD2 stimulation induces autophagy in
dendritic cells (DCs) and requires ATG5, ATG7, and
ATG16L1. NOD2-mediated autophagy affects bacterial han-
dling and antigen presentation in DCs.38 NOD2 recruits
ATG16L1 to the plasma membrane upon bacterial entry in
epithelial cells.39Autophagy has been identified as a key process in host
resistance to bacterial infection, but some pathogens
(Brucella, Francisella, Listeria) can subvert autophagy and
generate their own intracellular niche. So far, little is known
of the steps by which pathogens manipulate the cell to evade
the autophagy pathway. Type III secretion, in host–pathogen
interaction, represents a potent subversion tool.40 How do
cells recognize intracellular bacteria and how is autophagy
subversion/avoidance achieved is not clear. Identifying
novel components of the autophagy apparatus are expected
from future studies.41
D.M. Monack (USA) explained that multiple inflamma-
somes direct innate immune responses against Salmonella.
NOD-like receptors (NLRs) sense intracellular pathogens and
endogenous danger signals in the cytosol.42,43 Activated
NLR's assemble a multiprotein complex called inflammasome
that leads to the production of caspase-1, which triggers
release of proinflammatory cytokines IL-1β and IL-18. Two
inflammasome receptors, Nalp3 and Ipaf, are necessary to
fully activate caspase-1 in response to intracellular pathogen
Salmonella typhimurium. Mice deficient for both Nalp3 and
Ipaf are markedly more susceptible to S. typhimurium
infection.
W. Marlicz (Poland) reported an increase in the number of
very small embryonic like stem cells (VSELs) in peripheral
blood of patients with IBD. These circulating cells are
significantly enriched for mRNA for gastrointestinal lineage
(lgr-5 and ASCL-2) and pluripotent stem cell markers (Oct-4,
SSEA-4, Nanog) as well as CXCR4 receptor. The number of
mobilized/circulating VSELs correlated in IBD patients with
elevated serum levels of stromal derived factor-1 as well as
hepatocyte growth factor and vascular endothelial growth
factor. The biological and clinical significance as well as the
true regenerative potential of these cells in regeneration of
injured gut tissue is unclear.
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sition (EndoMT) was advocated as a novel mechanism of
fibrosis in IBD (F. Rieder, USA). The combination of TGF-β1,
IL-1β and TNF-α induces morphologic and phenotypic
changes in human intestinal microvascular endothelial cells
consistent with EndoMT, and these were reproduced using
supernatants of activated lamina propria mononuclear cells.
The changes persisted after removal of the inducing agents.
EndoMT can be detected in microvessels of IBD mucosa and
TNBS-induced colonic fibrosis in mice. These data suggest
that inflammation induces trans-differentiation of mucosal
microvascular cells into mesenchymal cells, supporting the
notion that the microvessels contributes to IBD-associated
fibrosis through the process of EndoMT.5. Innate immunity
IBD is characterized by a disregulated response of intestinal T
cells as well as other immune cell types. The mechanisms
responsible for the induction of pathogenic T cells are still
undefined, but recent progress has highlighted the critical
roles of commensal bacteria, the innate immune system,
myeloid cells (Dcs and macrophages), Th17 cells and
regulatory T cells (Treg). In particular, analysis of Th17
responses has elucidated both pathogenic and protective
roles of the cytokines produced by these cells in the
development of colitis. Mounting evidence indicates that
different innate signaling pathways (for example, IL-23-
driven, versus TGF-β and IL-6-driven) may have differential
roles in the generation of pathogenic, non-pathogenic or
protective Th17 responses.44 Furthermore, it is becoming
clear that the commensal bacterial composition plays a
critical role in the differential induction of pathogenic and
protective T cell responses in the intestine.45
DCs play a pivotal role in the control of intestinal
inflammation (H.C. Reinecker, USA). DCs form the major
antigen-presenting cell population involved in T cell priming.
In the intestine, a combination of conventional (cDCs),
migratory (mDCs) and plasmacytoid-derived DCs (pDCs)
create a surveillance system that is constantly engaged in
sampling and processing of food antigens as well as
commensal and pathogenic microbiota. Different DCs with
distinct functions populate Peyer's patches, mesenteric
lymph nodes and the small and large intestine immune
function. DC precursors from bone marrow stem cells have
been identified.46,47 DCs play a central role in mucosal
inflammation through CD40-mediated responses by directing
T and B cell trafficking in the intestine, and by limiting
mucosal injury through the induction of Foxp3+ Tregs by
CD103+ DCs and lamina propria mDCs. DCs have also been
linked to the induction of IL-17 secretion.
FMS-like tyrosine kinase 3 ligand (Flt3L) is a key regulator
of human and mouse DC function.48–50 Flt3L drives the
differentiation of bone marrow progenitors into all DC
subsets including pDCs. Flt3L is required for maintenance
and expansion of lymph node and organ specific DCs. Flt3L is
increased during inflammatory conditions and expressed by
activated T cells and stromal cells. Stat3 is a downstream
transcriptional effector of Flt3 signaling. One third of acute
myeloid leukemias carry constitutive active Flt3 mutations.Flt3L directly or indirectly inhibit IL-10 production by Foxp3+
regulatory T cells.
Dendritic cell autoimmune modifiers (DCAMs) have been
proposed for the treatment of intestinal inflammation.
These include new series of imidazoacridinones which are
based on potent FLT3 receptor tyrosine kinase inhibitors.
Some of these compounds show efficiency in inhibiting
experimental autoimmune encephalomyelitis (EAE) and
rheumatoid arthritis, and have been optimized for oral
delivery and inhibition of intestinal inflammation. DCAMs
protect C57BL/6 mice from DSS-induced colitis, promote
mucosal recovery from DSS colitis, inhibit proinflammatory
cytokine production in mesenteric lymph nodes during
chronic DSS colitis.
M. Lotze (USA) drew attention to damage associated
molecular patterns (DAMPs), redox and autophagy. Pathogen
or damage associated molecular pattern (PAMPs and DAMPs,
respectively) are molecules that promote the inflammatory
response by recognizing exogenous and self products,
respectively.51 One of the best characterized DAMPs is the
high mobility group B1 (HMGB1), which is located in the
nucleus, cytosol, and mitochondria. Ethyl pyruvate, which
inhibits HMGB1 release, decreases inflammation, and
improves survival in sepsis and hemorrhagic shock and
ameliorates colitis and reduces intestinal cytokine produc-
tion in IL-10−/− mice.52 Anti-HMGB1 antibodies can be
effective in several conditions including endotoxemia,
arthritis, acute lung injury, ischemia reperfusion injury,
hemorrhagic shock, colitis, pancreatitis, cerebral ischemia
and cancer. HMGB1 activation of the induced receptor for
advanced glycation end products (RAGE) initiates NF-κB and
MAP kinase signaling, resulting in propagation and perpetu-
ation of inflammation. The HMGB1/RAGE pathway regulates
metabolism and autophagy in experimental colitis and
cancer models.53 Endogenous and exogenous rHMGB1
enhances autophagy and limits RNA viral replication. HMGB
proteins function as universal sentinels for nucleic-acid-
mediated innate immune responses.54 Knockout of HMGB1
impairs mitochondrial function, causes a profound loss of
oxidative phosphorylation and reduces cell survival. Induc-
tion of immunological tolerance by apoptotic cells requires
caspase-dependent oxidation of HMGB1 protein.55 DAMP
molecules and reduction/oxidation appear to regulate
immunity.51,56
DAMP micro RNAs (miRs) have been identified. miR-34c
expression increases in HMGB1 wild-type lysate-exposed
peripheral blood mononuclear cells (PBMC). miR-214
increases in both HMGB1 wild-type and HMGB1 knockout
lysate-exposed PBMCs. miR-155 is a PAMP miR. Transfection
of pre-miR-34c into human PBMCs and subsequent exposure
to lysate leads to decreased IKKγ (NEMO) protein and mRNA
expression.
Recent studies have suggested that epigenetic regulation
of the inflammatory response may play a role in chronic
inflammatory diseases (L. Backdahl, Sweden). Epigenetic
modulation may account for some additional expression
regulation other than genetic.57 Specifically, epigenetic
marks include histone methylation, acetylation, phosphory-
lation and ubiquitylation. DNA methylation is the most
common epigenetic modification and occurs nearly exclu-
sively at cytosines in CpG dinucleotide enriched areas, which
are often located in the promoter region of many genes. For
697News from the “5th international meeting on inflammatory bowel diseases” CAPRI 2010instance, hypermethylation of promoter regions often
results in gene silencing, while promoters of transcriptionally
active genes are typically hypomethylated.58 DNA methyla-
tion is considered to be a specifically suitable epigenetic
mark to assess terminal reprogramming in chronic inflam-
mation.59 DNA methylation provides the main link between
the genetics of the disease and the environmental compo-
nents that plays a decisive role in the aetiology of IBD.
Possible triggering environmental factors are nutrition,
smoking, hygienic conditions, or medical treatments.
Epigenetic reprogramming is critical in the activation and
differentiation/maturation of the immune response.60 Differ-
entiation of Th1/Th2 cells is determined by changes in
epigenetic status at their signature loci. This is particularly
true for Treg cells where demethylation in the Foxp3 promoter
is a hallmark for this T cell population. Also B cells and the cells
involved in innate immunity show differences in their
epigenetic profile after stimulation with certain immune
response triggers.
Regulation of cell differentiation depends on both the
gene expression profile and the epigenetic profile. Epige-
netic variation can be responsible for the ultimate pheno-
typic expression (disease). Therefore, identifying disease-
specific epigenetic marks in the genome would provide
excellent clues to disease pathways as well as serve as
potential therapeutic targets. Epigenetic modifiers such as
histone deacetylase inhibitors and inhibitors of DNA meth-
ylation seem to have therapeutic effects in chronic inflam-
matory diseases.59 5-AZA-cytidine, an inhibitor of DNA
methyltransferases (DNMT1) seems to be a promising
compound in this respect.
E. Cario (Germany) showed that deletion of TLR2
promotes Th1-mediated inflammation in MDR1 deficiency.
Loss of TLR2 dramatically aggravates commensal-dependent
colonic inflammation in MDR1−/− mice. This study identifies
TLR2 as an important inhibitor of aberrant −Th1 cell
activation in the absence of MDR1. Thus, UC patients with
combined genetic defects in TLR2 and ABCB1 (MDR) may
exhibit a more severe disease phenotype.
O. Brain (UK) reported the molecular mechanism by which
NOD2 induces autophagy in DCs, using a combination of
proteomic approaches. CD patients expressing NOD2 or
ATG16L1 variants have defective NOD2-mediated autop-
hagy, which influences antigen presentation and bacterial
handling. This may result in deficient bacterial clearance.
DCs from CD patients expressing NOD2 variants exhibit
failure in muramyl dipeptide mediated autophagy and LC3
localization with HLA DR. ATG7 and HMGB1 may be potential
links to NOD2-mediated autophagy induction.Figure 3 Microbiota, Th17 cells, and mucosal protection
(Courtesy of D.R. Littman, USA).6. Adaptive immunity
The role of the microbiota and transcriptional regulators in
Th17 cell differentiation was analyzed in detail by D.R.
Littman (USA). IL-17-producing CD4+ T lymphocytes, while
important for mucosal immunity, have also been implicated
as major contributors to tissue inflammation and are thought
to be involved in human autoimmune diseases, including
IBD.61 Lymphoid lineage cells that share the property of
producing IL-17, IL-17F, and IL-22 include αβ T cells (CD4
cells primarily, but also some CD8 cells), γδ T cells, LTi cells,and NK-like cells. All of these cell types express IL-23R,
RORγt, and AHR (and CCR6?). In the absence of RORγt, T cells
do not make IL-17 or IL-22 and LTi and NK-like cells do not
develop. In the absence of AHR, none of these lymphoid cells
make IL-17 or IL-22 and clearance of pathogenic bacteria is
impaired.
RORγt is a key transcription factor regulating Th17 cell
development. Although critical for Th17 cell differentiation,
RORγt function is integrated with that of other nuclear
factors, namely STAT3, IRF-4, and BATF, that have also been
demonstrated to be essential; and AHR and Runx-1, that
contribute in a more restricted manner to Th17 cell
differentiation. RORγt appears to be a promising target for
anti-Th17 therapy. In fact, small molecule inhibitors of
RORγt activity, by blocking Th17 cell differentiation,
improve mouse models for autoimmunity. RORγt-deficient
T cells fail to induce EAE or transfer colitis.
A fine balance between Th17 and Treg phenotypes exists
and appears to be governed by the concentration of TGF-β
and by an interaction of RORγt with Foxp3, as well as by the
composition of the commensal microbiota.62,63 Antibiotics
reduce Th17 cell differentiation in the small intestinal
lamina propria. In germ-free mice, Th17 cells are absent
and the proportion of Treg cells among the CD4+ T cells is
substantially increased.63 Gram-positive spore-forming
anaerobes closely related to Clostridia, namely segmented
filamentous bacteria (SFB), appear to be responsible for the
accumulation of Th17 cells in the intestine.64,65 SFB
colonization protects host from Citrobacter-induced colitis
from one hand, but also correlates with increased suscepti-
bility of mice to autoimmune disease from the other (Fig. 3).
SFB colonization of germ-free mice enhances frequency of
Th17-mediated spontaneous arthritis (K/BxN model). All
these findings illustrate the importance of maintaining an
appropriate commensal bacterial-regulated balance be-
tween effector T cells and Treg cells. How specific microbial
products influence the differentiation of the lamina propria
RORγt- and AHR-expressing lymphoid cells as well as Treg
cells is an area that is increasingly recognized to be of central
importance in pathogenesis of IBD.
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role of IL-23 and STAT-3 pathways in influencing the balance
between tolerance and immunity in the intestine.66–69
Intestinal homeostasis is a balancing act between effector
and regulatory T cells. The intestine is a preferential site for
differentiation of Foxp3+ Treg cells . Functionally distinct DC
subsets promote Treg development via TGF-β and retinoic
acid dependent mechanism. During inflammation, IL23
produced by DCs restrains regulatory T cells and promote
Th17 effector cells. The importance of the IL23/IL17
pathway in IBD is supported by several findings: multiple
SNPs in genes involved in this pathway are associated with
IBD, Th17 cytokines are increased in colon and blood of
patients and drive T cell dependent colitis. IL-23 drives
colitis by promoting the development of IFN-γ and Th17 cells
and inhibiting Foxp3 Treg cells. A conserved IL-23/RORγt
inflammatory axis in innate and adaptive lymphoid cells in
the intestine appears to be present.
The role of effectors T cells in IBD was discussed by M.
Neurat (Germany). Differences in T cell subsets, effector
cytokines, transcription factors, and perpetuating cytokines
have been found between CD and UC70–73 (Fig. 4). In CD
T cells produce large amounts of Th1 cytokines such as IFN-γ
and IL-12, while in UC colitis produce more Th2 cytokines
such as IL-5 and IL-13. IL-13 has been suggested to alter
barrier function and epithelial integrity in UC. Th1 associat-
ed transcription factor T-bet was found to be induced in CD
but not UC, where the GATA3 factor prevails. T-bet
transactivates the IFN-γ promoter, induces chromatin remo-
delling at the IFN-γ locus, and induces IL-12 receptor β2 chain
expression. Recent studies suggest that IBD is associated with
Th17 cells and Th17-associated cytokines (IL-17A/F, IL-21 and
IL-22).61,66 An upregulation of the Th17 associated transcrip-
tion factors RORA and RORC has been found in IBD patients and
seems to play an active role in intestinal damage.
The IL-6/sIL6R system shows a crucial role in experimen-
tal colitis with both proinflammatory and protumorigenic
functions. Both IL-6 and sIL-6R blockade suppresses tumor-
igenesis in the DSS/AOM model.74,75 The nuclear factor of
activated T cells (NFAT) family of transcription factors
controls calcium signaling in T lymphocytes. NFATc2 plays a
critical role in experimental colitis by controlling T cellFigure 4 Key cytokine targets in IBD (Courtesy of M. Neurath,
Germany).derived cytokines.76 NFATc2 controls IL-6 production and
subsequently T cell apoptosis and Th17 cytokines. NFATc2
emerges as an attractive target for therapy of IBD.
Interferon regulatory factor (IRF)-4 selectively controls
cytokine gene expression in chronic intestinal inflamma-
tion.77,78 IRF-4 controls T cell dependent experimental
colitis. IRF-4 knockout mice are protected from experimen-
tal oxazolone and TNBS colitis. IL-6 treatment prevents the
protective effects of IRF-4 deficiency.
Retinoic-acid-related orphan receptor (ROR)γ deficient
T cells lack colitogenicity. Neither IL-17A, nor IL-17F or IL-22
expression alone in T cells is necessary for colitis induction.79
IL17A and IL17F seem to have redundant functions in the gut.
Neutralization of both IL-17A and IL-17F protects animals
from colitis. IL-17A rescues colitis in RAG−/− mice trans-
ferred with RORγ−/− T cells. Th17 are also important in the
T cell transfer colitis model.
R. Alaniz (USA) presented a humanized mouse model of
IBD and microbial immunity. The results of the study support
the notion that HLA-DQ8-restricted CD4+ T cell responses to
microbial targets exacerbate the severity of IBD after enteric
bacterial infection, and the evaluation of HLA-restricted
antigens in a humanized mouse model are important for IBD
research.
M.C. Fantini (Italy) reported that Smad7 expression in
T cells protects from colitis-associated colorectal cancer
even in the presence of strong colonic inflammation.
Protection is at least in part due to IFN-γ expressed by
Th1, cytotoxic T cells (CTL) and NK/NKT cells into the
tumoral and peritumoral areas of the colon. Accumulation of
IFN-γ-expressing CTL and NK/NKT cells correlates with high
expression of the cytotoxcity markers (i.e. perforin1,
granzyme B and FasL) and induction of apoptosis in dysplastic
epithelial cells.7. Developments in clinical IBD
A critical overview to improve understanding of clinical trials
in IBD was presented by M. Lémann (France). Clinical trials
aiming at supporting a new first line indication should always
include comparison with the accepted first line treatment.
The trial aiming at demonstrating superiority should (when
ethically justifiable) also include a placebo arm to provide
internal validation of the study. A three-armed trial with
test, reference and placebo is the recommended design
(EMEA 2005). The critical points of induction (4–12 weeks)
and maintenance (6–24 months) clinical trials in IBD were
examined. In induction trials in IBD is crucial: 1) demonstrate
efficacy (the test product arm is superior to placebo or is
superior (or non inferior) to an active comparative drug),
2) define the target population (‘active’ disease susceptible
to be improved by the test product without interactions with
concomitant medications); 3) define endpoints (definition
and timing of primary, secondary, exploratory).80 In main-
tenance trials in IBD the selection of remitters and/or
responder to study drug, as well the long term remission are
crucial.
Trials combining induction treatment and maintenance
treatment should preferably only enter patients that have
achieved remission (in either the trial drug or comparison
group), into maintenance phase and preferably a re-
699News from the “5th international meeting on inflammatory bowel diseases” CAPRI 2010randomisation should be done. Clinical trials are mainly
devoted to demonstrate efficacy and safety of new products,
but the rules are strict and the selection of patients and
endpoints must be optimized. It should be remembered that
clinical trials do not reflect real life because of the short
time and black and white endpoints. Others studies are
needed to define the best strategies, including comparative
studies, prospective cohorts, sequential or combined ther-
apies, and more practical endpoints.
G. D'Haens (Belgium) performed a critical analysis of risk-
benefit in biological therapy. The risk-benefit ratio is
conditioned by modality (“over” treatment in mild disease or
“under” treatment in severe disease) and type of treatment
(combination of drug such as corticosteroids, immunosuppres-
sants and biologics). Adverse events with immunomodulators
and biologic therapies for IBD are common. Fortunately, the
majority of these events are mild and transient. Clinicians
need to be aware, however, that serious problems can occur
including agranulocytosis and sepsis, potentially dangerous
opportunistic infections, malignancy (cancer or lymphoma),
immunogenicity and loss of response, injection and cytokine
release reactions, autoimmunity, heart failure, and demye-
lination. In particular, patients who use biologic therapies in
combination with classic immunomodulators appear to carry
an elevated risk for these problems.81 In general, the benefits
of biological therapies outweigh the risk in properly studied
patients. Adherence to the European Crohn's and Colitis
Organization (ECCO) guidelines will probably further reduce
the risk of complications.82 The efficacy of the treatment
needs to be balanced against the severity of these adverse
events. The presence or absence of therapeutic alternatives
also needs to be taken into account. IBD therapies do not
always need to be continued lifelong; withdrawal strategies
need to be refined. Monotherapy regimens usually give fewer
adverse events in the long run. Prolonged corticosteroid use
and deep immunosuppression should be avoided.
L. Beaugerie (France) extensively discusses the problem of
Epstein–Barr virus (EBV) and lymphoma in IBD. Lymphomas
often develop in intestinal segments affected by IBD and are in
most cases associated with EBV.83 Chronic intestinal mucosa
inflammation constitutes a risk factor for subsequent lympho-
proliferative disorders (LD) like for high-grade dysplasia or
adenocarcinoma. If confirmed, a sustained mucosal healing of
intestinal lesions could be associated with a reduction in the
risk of intestinal inflammation-associated LD. EBV infection
could be an important cofactor, especially in patients
receiving immunosuppressants that promote reactivation of
latent EBV infection. Therapy is associated with a moderately
increased risk of LD. Patients receiving thiopurines have a 3 to
5-fold increase in the risk of LD compared with patients naïve
to thiopurines or those who discontinued the drug,84 even
though the overall risk is very low. Most of the excess cases of
LD affect young adults. It should be assessed whether a
progressive increase in the systemic EBV viral load may
precede in some cases the clinical onset of LD in IBD. If this
is confirmed, the sequential measurement of systemic EBV
viral load could emerge as a routine clinical tool for managing
the risk of EBV-associated LD in IBD patients receiving
thiopurines. The recently identified risk of hepatosplenic
T cell lymphoma in young male IBD patients co-treated with
anti-TNFα and thiopurines is low and does not appear as
associated with EBV infection.85The reasons of treatment failure during IBD therapy were
analyzed both from basic and clinical points of view. From a
basic point of view a distinction between primary (failure at
initial trial) and secondary (failure after initially responding)
failure of medical treatment was made (C. Elson, USA).
Primary failure may be related to heterogeneity of IBD as
supported by the large number of risk alleles identified in
GWAS studies of IBD; drugs effective for one gene defect
might not work for another. More risk alleles and modifiers
are associated to more severe disease and lower response to
therapy.86 Primary failure may also be related to metabolism
of the drug by various enzyme systems or membrane
transporters, i.e. cytochrome P 450 system and multi-drug
resistance gene 1. Secondary failure of medical therapy is
more common with the biologic therapies than with non-
specific immune modulator therapy. The mechanisms of
secondary failure are presently unknown, although may, in
part, be related to the formation of antibodies (immuni-
genicity). However, one potential mechanism has been
revealed in recent findings of plasticity of the adaptive
CD4 T cell immune response. Although CD4 Th1 and Th2 cells
are reasonably stable, Th17 and Foxp3 Tregs can turn into
other subsets, i.e., exhibit plasticity.87 The molecular basis
of this appears to be interactions between the transcription
factors RORγt for Th17 cells and Foxp3 for Treg cells.
Another possible mechanism could be the micro RNA (miR)
system, small sequences of RNA that interact with genes and
alter their transcription.88 Altered miR expression under the
pressure of biologic therapy may result in escape from the
beneficial effects of the therapeutic agent. A third possible
mechanism for secondary failure could be the shift in the
microbiota toward microbes with more proinflammatory
effects that make the immune system less responsive to
biological agents. It is likely that a better understanding of
the mechanisms involved in drug failure (“biologic escape”)
would help shape better therapeutic strategies.
From a clinical point of view,mechanisms of failure include
sub-therapeutic blood concentrations, symptoms without
evidence of active disease by laboratory, endoscopic, and
radiographic criteria, and undiagnosed and untreated co-
morbidities (W. Sandborn, USA). Co-morbidities that cause
symptoms in patients with IBD, in particular with CD, include
disease complications (strictures, fistulas, abscesses), compli-
cations of surgical resection (bile acid diarrhea, steatorrhea,
small bowel bacterial overgrowth), irritable bowel syndrome,
infections (Clostridium difficile, Cytomegalovirus), and de-
pression. In documented active disease (presence of clinical
symptoms, endoscopic and radiological findins, as well as
positivity of biomarkers), sub-therapeutic concentrations of
steroids, immunomodulators and biological agents may be the
cause of medical failure.
The clinical impression of gastroenterologists based on
the patient's history is frequently incorrect and is insufficient
to make proper therapeutic decisions. Colonoscopy and CT or
MRI enterography should be routinely employed prior to any
major changes in therapy: 1) Before starting steroids,
immunosuppressives or biologicals; 2) When patients fail to
respond to steroids, immunosuppressives or biologicals;
3) When patients receive maintenance therapy with immu-
nosuppressives or biologicals relapse; 4) Before surgery.
Treatment of patients who have no documented evidence of
active disease with steroids, immunosuppressives, or
Figure 5 Paradigm for Integration of Research & Clinical Care (Courtesy of D. Podolsky, USA).
700 G. Latella et al.biological agents will not address the cause of the symptoms
and will expose the patients to risks that may be unneces-
sary. These patients with persistent symptoms should be
systematically evaluated for bile acid diarrhea, steatorrhea,
bacterial overgrowth, and depression.
W. Van Moerkercke1 (Belgium) showed that mucosal
healing in CD is associated with high infliximab trough levels.
Measurement of infliximab trough levels is therefore useful
in optimizing therapy since they may allow dose adjustment
in patients with low drug levels.
C. Rousseaux (France) presented the preclinical and
toxicological assessments of the novel orally bioavailable
PPAR ligand GED-0507-34-Levo for the treatment of IBD.
GED-0507-34-Levo molecule has strong intestinal anti-
inflammatory and analgesic properties. Its attractive safety
profile allows a phase 1 study scheduled in healthy
volunteers with GED-0507-Levo tablet coated with the
colonic drug release Multi-Matrix (MMX) system.
8. Integrating scientific knowledge
A very interesting tandem presentation was done by D.
Poldosky (USA) and D. Hommes (The Netherlands) on the
integration of research and clinical care in the future. The
presentationwas focused onmacrotrends affecting healthcare
delivery and research and the need to innovate traditional
infrastructures to deal with these changing trends as well as
the opportunities to accelerate scientific knowledge.
Hospitals are symptom-based and organized around
curative care. In the future we will be looking for a shift
from curative medicine to preventing care. A revolutionary
change is expected that involves the transfer of power and
authority from physicians to patients and third parties like
health-insurers. The physician/patient relationship will
move from paternal to collaborative. The traditional family
doctor will likely become obsolete in the future. Rapid
translation of scientific progress will be crucial for optimiz-
ing of healthcare service. This can be achieved if hospitals
integrate medical research and daily care in order to ensure
continuous innovation and personalized care (Fig. 5). Large
biobanks, fully integrated into the hospital infrastructure,
will become essential in the near future. Integrating the vast
molecular information will identify disease subtypes and
potential strategies for diagnosing and treating disease in
new and more effective ways.
9. Capri lecture
The Capri lecture 2010 was given by Carlo Croce, Director of
the Institute of Genetics and Director of the Human CancerGenetic Program, the Ohio State University, Columbus, Ohio
(USA). Prof. Croce gave a brilliant lecture entitled “From
observation to discovery in art and science”. He went along
the path of his research activity demonstrating that cancer is
a genetic disease due to somatic changes. He stressed the
fascinating common link between art and science in the
discovery of new findings. He concluded by showing some of
his discoveries in the field of classical painting using the same
methodology used for scientific research.Acknowledgements
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